Global High Sensitivity C-Reactive Protein Test Market Size By Type (Range 3-10mg/L, Range<3mg/L), By Application (Cardiovascular Disease, Inflammation), By Region, And Segment Forecasts, 2023 to 2032

The Global High Sensitivity C-Reactive Protein (hs-CRP) Test Market was valued at USD 1.2 billion in 2023 and is projected to surpass USD 2.1 billion by 2031, growing at a CAGR of 7.4% during the forecast period from 2023 to 2031. This growth is driven by the increasing prevalence of cardiovascular diseases (CVDs), heightened focus on early disease detection, and the growing adoption of preventive healthcare diagnostics. hs-CRP tests are highly sensitive biomarkers used to assess low levels of C-reactive protein in the blood, helping in the risk stratification of cardiovascular events and chronic inflammatory conditions.

Drivers

1. Rising Prevalence of Cardiovascular Diseases:

Cardiovascular disease remains the leading cause of death globally. hs-CRP tests are increasingly recommended by clinicians as a predictive tool for heart disease risk, prompting greater adoption in clinical settings.

2. Shift Toward Preventive Healthcare:

The healthcare industry's move from reactive to preventive care is boosting demand for biomarkers like hs-CRP that allow early risk identification and disease management.

3. Increasing Geriatric Population:

The aging population is more susceptible to chronic diseases, necessitating regular health monitoring through sensitive diagnostics such as hs-CRP tests.

Restraints

1. Lack of Awareness in Developing Regions:

Despite its diagnostic value, the hs-CRP test is underutilized in many low- and middle-income countries due to limited awareness and healthcare accessibility.

2. High Cost of Advanced Diagnostic Equipment:

While the test itself is cost-effective, the infrastructure and automation tools required for processing can be costly, limiting adoption in smaller labs and clinics.

Opportunity

1. Expansion in Home-based and Point-of-Care Testing:

Technological advancements are enabling the miniaturization of diagnostic tools, making hs-CRP testing feasible in home healthcare and decentralized settings.

2. Integration with AI and Predictive Analytics:

Combining hs-CRP results with machine learning models to predict cardiovascular and inflammatory risks is an emerging opportunity in precision medicine.

Market by System Type Insights

Based on system type, the Laboratory-based Analyzers segment accounted for the largest market share in 2023 due to their widespread use in hospitals and diagnostic labs. However, the Point-of-Care Testing (POCT) segment is expected to witness the fastest growth during the forecast period, driven by increased demand for rapid diagnostics in outpatient and remote settings.

Market by End-use Insights

In 2023, Hospitals held the largest share of the hs-CRP test market, owing to the integration of these tests into cardiovascular risk assessment protocols. Diagnostic Laboratories followed closely due to their role in routine health screenings. The Home Care Settings segment is expected to expand rapidly, fueled by the rise in consumer health awareness and telemedicine services.

Market by Regional Insights

North America dominated the global hs-CRP test market in 2023, attributed to advanced healthcare infrastructure, high prevalence of chronic diseases, and widespread insurance coverage. Europe followed closely, with increasing investment in preventive healthcare. Asia-Pacific is projected to experience the fastest growth, particularly in countries like China and India, where healthcare access and awareness are improving.

Competitive Scenario

Key players in the global hs-CRP test market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific, Beckman Coulter, Randox Laboratories, Bio-Rad Laboratories, and Danaher Corporation. These companies focus on expanding their diagnostic portfolios through innovation, automation, and global partnerships.

Key Developments:

In 2023, Roche Diagnostics introduced a next-generation hs-CRP assay compatible with its high-throughput analyzers.

Siemens Healthineers partnered with a health-tech firm in 2024 to incorporate AI analytics into cardiovascular diagnostic panels, including hs-CRP.

In 2025, Abbott launched a portable POCT device enabling hs-CRP testing in primary care clinics and mobile health units.

Scope of Work – Global High Sensitivity C-Reactive Protein Test Market

FAQs

1) What is the current market size of the Global High Sensitivity C-Reactive Protein Test Market?

The market was valued at USD 1.2 billion in 2023.

2) What is the major growth driver of the Global High Sensitivity C-Reactive Protein Test Market?

The rising prevalence of cardiovascular diseases and the growing shift toward preventive healthcare are key growth drivers.

3) Which is the largest region during the forecast period in the Global High Sensitivity C-Reactive Protein Test Market?

North America is the largest region, with Asia-Pacific expected to witness the fastest growth.

4) Which segment accounted for the largest market share in the Global High Sensitivity C-Reactive Protein Test Market?

The Laboratory-based Analyzers segment accounted for the largest share in 2023.

5) Who are the key market players in the Global High Sensitivity C-Reactive Protein Test Market?

Key players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific, and Bio-Rad Laboratories.